Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Non Operating Income (2016 - 2025)

Coherus Oncology's Non Operating Income history spans 13 years, with the latest figure at $1.8 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 48.13% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $7.0 million, down 8.03%, while the annual FY2025 figure was $7.0 million, 8.03% down from the prior year.
  • Non Operating Income for Q4 2025 was $1.8 million at Coherus Oncology, down from $2.1 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $2.9 million in Q2 2025 and bottomed at -$385000.0 in Q4 2021.
  • The 5-year median for Non Operating Income is $1.4 million (2022), against an average of $1.2 million.
  • The largest annual shift saw Non Operating Income crashed 6516.67% in 2021 before it surged 5300.0% in 2023.
  • A 5-year view of Non Operating Income shows it stood at -$385000.0 in 2021, then soared by 621.56% to $2.0 million in 2022, then plummeted by 106.42% to -$129000.0 in 2023, then soared by 1032.56% to $1.2 million in 2024, then soared by 48.13% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Non Operating Income are $1.8 million (Q4 2025), $2.1 million (Q3 2025), and $2.9 million (Q2 2025).